[quote][postedby]Originally Posted by needhairasap[/postedby]
Then I would lick the chocolate off of her jarjar… mmmmm
I guess well trust you jarjar. The guy who’s logic led him to believe histogen was holding the cure all ready lol… jarjar knows best.
To the rest, if histogens ceo and cisteralis himself both say they don’t have the fundibg to tesr orotocols etc that we suggest… that’s evidence for my theory. Evidence for your theory would be the existence of a cure… and I don’t see a cure around…[/quote]
Academic research doesn’t happen because the researchers are independently wealthy and use their own capital. It happens because they apply for grants (usually government money, sometimes money that’s already in the university system) and the grants are slated only for specific purposes.
When Dr. Garza says he doesn’t have the money, he means there’s no money earmarked for a PGE2 study right now in the grant pipeline at his lab.
Needhairasap, cal is absolutely right. You don’t understand how research is funded, you have no idea of what drives funding for specific projects. It’s not just a simple lack of money, it’s much more complicated than you think.
Plus, I’m afraid the painful reality is that these researchers are MOSTLY involved in conducting small incremental studies which perpetuate their own salaries through grant awards. Each individual study in academic research is only intended to move the total understanding by a few microns. It’s intentionally done that way, because that’s how they make their living.
As soon as something really BIG and remarkable is found, it’s immediately sold to some big pharma company which has the capital to do clinical trials and market the drug.
People also don’t understand Follica. Follica is a business opportunity, a highly leveraged, low-budget company basically built on semi-vaporware, in that they acquired rights to what is essentially an immature technology, from Dr. Cotsarelis. It is not quite a “shell” company, but has some of the attributes of that unfortunate trend in US business: the company set up only for its directors to eventually cash out of. Exit strategy is everything.
I say it’s an immature technology because they have the skin perturbation (wounding) part, but what they don’t have is the drug to apply which will serve as a silver-bullet to maximize the potential of the skin perturbation.
Right now they’re trying (desperately, I think), to find that compound that, coupled with wounding, will deliver results impressive enough to get funding or sell to a big pharma company.
When they acquired rights to this idea, they should have thought harder about the fact that it was an immature technology.
All the articles we’re seeing in Xconomy, HuffingtonPost, Wall Street Journal, etc. IMO, are part of a big PR push by the company to create a buzz that will lead to some VC or other big source of capital talking to them about more funding and getting them to the point to where they can finance big clinical trials.
But they don’t even have the optimum candidate drug yet to use in those clinical trials, and that’s a big problem. It’s a Catch 22 in getting funding.
The key takeaway point here is that they DO NOT have that silver bullet magic compound yet that, together with the wounding, will grow an impressive amount of hair. And they may NEVER have that compound, because inherently the wounding thing might be something that, while it can induce a little bit of hair, really doesn’t have the potential to generate a lot of hair.
If they had that magic bullet compound by now, believe me, we’d know about it. And if they don’t find that compound pretty soon, whatever little funding they still have is going to dry up, some of the principals like the CEO are going to lose interest, they may sell their IP at a loss, and they’ll be history.
It may be better just to inject stem cells or progenitor cells directly, as Dr. Nigam is doing, rather than taking this roundabout, indirect and backdoor approach of wounding the scalp, just to get around FDA prohibitions on using cultured stem cells.